Persistent clinical efficacy and safety of anti-tumour necrosis factor \textgreeka therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response [PDF]
, 2008 Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS).
Alten, R. +11 more
core +1 more source
Adverse reactions of biological therapies in patients with psoriasis [PDF]
, 2017 Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp.
Georgescu, Simona R. +5 more
core +4 more sources
BMJ Open Gastroenterology, 2021 Background Infliximab is an efficacious therapy for inflammatory bowel disease and may play a role in management of some extraintestinal manifestations.
Daniel J Stein +6 more
doaj +1 more source
Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis
Case Reports in Dermatology, 2017 A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled ...
Yuki Matsuura-Otsuki +3 more
doaj +1 more source
Inflammatory Intestinal Diseases, 2021 Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD).
Manuel Sutter +2 more
doaj +1 more source
PLoS Biology, 2019 During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy.
Yun-Chi Lu +13 more
doaj +1 more source
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Respiratory Research, 2022 Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis.
Abdullah Sakkat +9 more
doaj +1 more source
Efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn’s disease patients who failed infliximab therapy: The Italian society of pediatric gastroenterology, hepatology, and nutrition experience [PDF]
, 2019 Background: Adalimumab (Ada) treatment is an available option for pediatric Crohn’s disease (CD) and the published experience as rescue therapy is limited.
Accomando S. +15 more
core +1 more source
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity [PDF]
, 2010 Introduction: This study is based on the results from a Belgian expanded access program in which patients with active refractory and erosive rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab in combination with methotrexate.
Vander Cruyssen, Bert +3 more
core +1 more source
Therapeutic Advances in Gastroenterology, 2015 Objectives: Many patients with Crohn’s disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied.
Douglas L. Nguyen +5 more
doaj +1 more source